Merck & Co. Alliance revenue - Koselugo — Milestone payments increased by 50.0% to $75.00M in Q3 2028 compared to the prior quarter. Year-over-year, this metric grew by 50.0%, from $50.00M to $75.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals successful progress in product development or commercialization, while a decrease may indicate delays in meeting project milestones.
This metric captures revenue recognized upon the achievement of specific, pre-defined events within a collaborative arra...
Standard in pharmaceutical R&D collaborations where payments are tied to clinical or regulatory success.
mrk_segment_alliance_revenue_koselugo_milestone_payments| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q3 '26 | Q3 '27 | Q3 '28 | |
|---|---|---|---|---|---|---|---|
| Value | $43.75M | $43.75M | $43.75M | $43.75M | $50.00M | $50.00M | $75.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +14.3% | +0.0% | +50.0% |
| YoY Change | — | — | — | — | +14.3% | +0.0% | +50.0% |